FLUDARABINE PHOSPHATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fludarabine Phosphate, and what generic alternatives are available?
Fludarabine Phosphate is a drug marketed by Actavis Llc, Actavis Totowa, Areva Pharms, Fresenius Kabi Usa, Hikma, Hospira, Mylan Labs Ltd, Rising, Sagent Pharms Inc, and Sandoz. and is included in eleven NDAs.
The generic ingredient in FLUDARABINE PHOSPHATE is fludarabine phosphate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fludarabine phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fludarabine Phosphate
A generic version of FLUDARABINE PHOSPHATE was approved as fludarabine phosphate by HIKMA on August 28th, 2003.
Summary for FLUDARABINE PHOSPHATE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 478 |
Patent Applications: | 2,293 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FLUDARABINE PHOSPHATE at DailyMed |
Recent Clinical Trials for FLUDARABINE PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
James Michael Martin | Phase 1 |
Invectys | Phase 1/Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Pharmacology for FLUDARABINE PHOSPHATE
Drug Class | Nucleoside Metabolic Inhibitor |
Mechanism of Action | Nucleic Acid Synthesis Inhibitors |